Covovax is likely to be available on the portal in a few days at a price of Rs 225 per dose plus applicable GST.
The DCGI's approval came following recommendation by the Subject Expert Committee of the Central Drugs Standard Control Organisation (CDSCO).
The DCGI approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022, and also in children aged 7-11 years on June 28, 2022 subject to certain...
The Drugs Controller General of India (DCGI) had on January 16 approved the market authorisation for Covovax for those who have been administered two doses of either Covishield or Covaxin.
Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India (SII), had recently written to the DCGI for the approval of Covovax heterologous booster dose for those aged 18 years and...
Covovax is manufactured by the SII through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorisation.
Based on three phases of clinical trials, the overall efficacy rate of Covovax is estimated at around 89 per cent.
Serum Institute of India chief executive officer Adar Poonawalla on Sunday said its Covovax vaccine will get approval as a booster in the next 10 to 15 days, adding it works well against the Omicron variant of coronavirus.
The DCGI had approved Covovax for a restricted use in emergency situations in adults on December 28, 2021 and for those in the 12-17 age group, subject to...
According to the letter, the firm is also receiving requests from various sections of the society pan India to make vaccine available in government and private...
As verified by anonymous sources, The Drugs Controller General of India (DCGI) approved India's first indigenously developed mRNA vaccine against COVID-19...
The DCGI is set to review the applications of the Serum Institute of India, which has sought the authorization of Covovax vaccine among kids between 2-7 and...
India began inoculating children aged 12-14 from March 16. Biological E's Corbevax is being used to inoculate them.
India's drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12 to 17 years age group subject...
The Drugs Controller General Of India (DCGI) has already approved Covovax for restricted use in emergency situations in adults on December 28.
Director-Government and Regulatory Affairs at Serum Institute of India (SII) Prakash Kumar Singh had submitted an application to the DCGI on February 21,...
Covid-19: The India has approved the use of Corbevax and Covovax against the virus, while the anti-viral drug Molnupiravir has been given approval to be used...
The Covovax/Novavax vaccine has recently received Emergency Use Listing (EUL) with the World Health Organisation (WHO), Emergency Use Authorization (EUA) in...
All the recommendations of the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) have been sent to the Drugs Controller...
